{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:13:45Z","timestamp":1762100025166},"reference-count":17,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2002,1,2]],"date-time":"2002-01-02T00:00:00Z","timestamp":1009929600000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,12,27]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Esomeprazole is the first proton pump inhibitor to be developed as an optical isomer for the treatment of acid\u2010related diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Four hundred and forty eight duodenal ulcer patients with <jats:italic>Helicobacter pylori<\/jats:italic> infection, confirmed by <jats:sup>13<\/jats:sup>C\u2010urea breath test (UBT), and no current ulcer, were randomised to double\u2010blind treatment with esomeprazole 20\u2003mg twice daily (b.d.) (<jats:italic>n<\/jats:italic>=224) or omeprazole 20\u2003mg b.d. (<jats:italic>n<\/jats:italic>=224), in combination with amoxicillin 1\u2003g b.d. and clarithromycin 500\u2003mg b.d. for 1\u2003week (EAC and OAC, respectively). A negative UBT at both 4 and 8\u2003weeks after completing therapy indicated successful <jats:italic>H. pylori<\/jats:italic> eradication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Intention\u2010to\u2010treat (ITT) analysis comprised 400 patients (EAC, <jats:italic>n<\/jats:italic>=204; OAC, <jats:italic>n<\/jats:italic>=196) and per protocol (PP) analysis 377 patients (EAC, <jats:italic>n<\/jats:italic>=192; OAC, <jats:italic>n<\/jats:italic>=185). Eradication rates (95% confidence intervals) for ITT and PP populations were: EAC, 90% (85\u201394%) and 91% (86\u201394%); OAC, 88% (82\u201392%) and 91% (86\u201395%). Between\u2010group differences in eradication rates were not statistically significant. Both regimens were well tolerated, with an adverse event profile and frequency typical of proton pump inhibitor plus antibiotic combination therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Esomeprazole\u2010based triple therapy for 1\u2003week is highly effective in eradicating <jats:italic>H. pylori<\/jats:italic> infection in duodenal ulcer disease, offers comparable efficacy to omeprazole\u2010based therapy, and is well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00911.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:40:37Z","timestamp":1047354037000},"page":"1605-1611","source":"Crossref","is-referenced-by-count":42,"title":["One\u2010week triple therapy with esomeprazole provides effective eradication of <i>Helicobacter pylori<\/i> in duodenal ulcer disease"],"prefix":"10.1111","volume":"14","author":[{"given":"S.","family":"Veldhuyzen Van Zanten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Lauritsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u2010C.","family":"Delchier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Labenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"De Argila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.\u2010C.","family":"Treichel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Stubber\u00f6d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cockeram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hasselgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"G\u00f6the","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wrangstadh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,2]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"13","article-title":"Helicobacter pylori","volume":"1999","author":"McColl KEL","year":"1988","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.1.8"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1155\/1998\/170180"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1155\/1999\/180751"},{"key":"e_1_2_6_6_2","first-page":"65","article-title":"Helicobacter pylori in peptic ulcer disease. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease","volume":"272","author":"NIH Consensus Conference","year":"1994","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.1996.03530320046033","article-title":"Medical treatment of peptic ulcer disease. Practice guidelines","volume":"6","author":"Soll A","year":"1996","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00027.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70119-8"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00535.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00471.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00813.x"},{"key":"e_1_2_6_13_2","unstructured":"AnderssonT R\u00f6hssK Hassan\u2010AlinM&BredbergE.Pharmacokinetics and dose\u2013response relationship of esomeprazole. Abstract. VIIth World Congress on Clinical Pharmacology and Therapeutics Florence Italy 15\u201320 July 2000."},{"key":"e_1_2_6_14_2","first-page":"S1","article-title":"Guidelines for clinical trials in Helicobacter pylori infection","volume":"41","author":"Working Party of the European Helicobacter pylori Study Group","year":"1997","journal-title":"Gut"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199908002-00007"},{"key":"e_1_2_6_16_2","first-page":"260","article-title":"H. pylori resistance to metronidazole and clarithromycin: effect on the outcome of eradication therapy","volume":"5","author":"Zanetti MV","year":"1999","journal-title":"Clin Microbiol Infect"},{"key":"e_1_2_6_17_2","first-page":"10","article-title":"Relationship between eradication therapy and clarithromycin\u2010resistant Helicobacter pylori in Japan","volume":"35","author":"Hoshiya S","year":"2000","journal-title":"J Gastroenterol"},{"key":"e_1_2_6_18_2","first-page":"1539","article-title":"The prevalence of esophagitis in patients with duodenal ulcer or ulcer\u2010like dyspepsia","volume":"91","author":"Boyd EJS","year":"1996","journal-title":"Am J Gastroenterol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00911.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00911.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00911.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T09:57:22Z","timestamp":1698573442000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00911.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12,27]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2000,12,27]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00911.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00911.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12,27]]}}}